EverHint – EMA 10/30 Crossover – Top 15 Buy and Top 5 Sell Signals for Sep 03, 2026
Excerpt: 20 signals (from 39 total). Healthcare leads (10). price range $5-$2203. 3 with insider selling.
What This Signal Is
Detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30), generating both buy and sell signals. Uses two EMAs instead of EMA + SMA, making it more responsive to price changes and better suited for capturing short-to-medium term momentum shifts.
Entry Criteria:
- Buy: EMA10 crosses above EMA30
- Sell: EMA10 crosses below EMA30
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 1-4 weeks | Risk level: Medium
Market Context
Broad equity markets are displaying strong bullish momentum heading into September 3, 2026, with all three major indices posting gains above 1% and the tech-heavy Nasdaq leading the advance at +1.40%. This synchronized rally across large-cap benchmarks signals healthy risk appetite and broad institutional participation, conditions that are generally favorable for trend-following strategies like EMA crossover systems. When markets move with this kind of directional conviction, short-term moving average crossovers tend to generate cleaner, more reliable signals with reduced whipsaw risk.
The VIX reading of 14.32, down nearly 6% on the session, reinforces a low-volatility, risk-on environment. Historically, VIX levels in the low-to-mid teens suggest options markets are pricing in relatively calm near-term conditions, which compresses intraday price swings and reduces the likelihood of false breakouts. For EMA-based signals, this is a double-edged dynamic — while reduced noise improves signal quality, tighter price ranges can also limit the magnitude of moves that follow a crossover, potentially compressing profit targets on shorter-duration trades.
The concentration of signals in the Healthcare sector warrants attention from a sector rotation perspective. Healthcare's emergence as the top signal-generating sector during a broad risk-on rally may indicate defensive rotation is quietly building beneath the surface, as investors hedge cyclical exposure while still participating in the upside. This divergence between market-level bullishness and sector-level defensive positioning suggests traders should monitor whether Healthcare momentum is driven by genuine sector strength or simply relative outperformance, as this distinction can meaningfully affect the durability of EMA crossover signals within that space.
🟢 Buy Signals (15 of 23 total)
Ranked by RSI (lower RSI for buy signals = more oversold)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | AESI | Atlas Energy Solutions... | Energy | $13.15 | — | $1.6B |
| 2 | ALNY | Alnylam Pharmaceutical... | Healthcare | $264.50 | — | $35.4B |
| 3 | ALV | Autoliv, Inc. | Consumer Cyclical | $125.02 | — | $9.2B |
| 4 | BFH | Bread Financial Holdin... | Financial Services | $108.79 | — | $4.4B |
| 5 | BLTE | Belite Bio, Inc | Healthcare | $171.09 | — | $6.9B |
| 6 | BRKR | Bruker Corporation | Healthcare | $59.41 | — | $9.0B |
| 7 | CELC | Celcuity Inc. | Healthcare | $96.43 | — | $4.7B |
| 8 | DAVE | Dave Inc. | Technology | $390.86 | — | $5.3B |
| 9 | FA | First Advantage Corpor... | Industrials | $21.02 | — | $3.6B |
| 10 | FBP | First BanCorp. | Financial Services | $28.45 | — | $4.3B |
| 11 | FCNCA | First Citizens BancSha... | Financial Services | $2203.43 | — | $25.1B |
| 12 | GGB | Gerdau S.A. | Basic Materials | $4.95 | — | $9.8B |
| 13 | HLI | Houlihan Lokey, Inc. | Financial Services | $136.86 | — | $9.6B |
| 14 | KR | The Kroger Co. | Consumer Defensive | $58.51 | — | $35.8B |
| 15 | KSS | Kohl's Corporation | Consumer Cyclical | $19.35 | — | $2.2B |
🔴 Sell Signals (5 of 16 total)
Ranked by RSI (higher RSI for sell signals = more overbought)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | ATR | AptarGroup, Inc. | Healthcare | $128.31 | — | $8.2B |
| 2 | AWI | Armstrong World Indust... | Industrials | $170.84 | — | $7.2B |
| 3 | BFLY | Butterfly Network, Inc. | Healthcare | $7.29 | — | $1.9B |
| 4 | BSX | Boston Scientific Corp... | Healthcare | $46.95 | — | $69.8B |
| 5 | COLD | Americold Realty Trust... | Real Estate | $14.11 | — | $4.0B |
Field Notes
Sector concentration: Healthcare (10), Financial Services (7), Industrials (6)
Data coverage: 7.7% insider (7d), 0.0% congressional (30d), 0.0% earnings, 23.1% news (7d)
Peer Analysis
FCNCA (First Citizens BancShares, Inc.): Leads 5 peers: HBAN ($17.06), RF ($30.44), CFG ($70.83), USB ($63.53), KEY ($22.12)
ATR (AptarGroup, Inc.): Leads 5 peers: STVN ($20.54), HSIC ($90.86), AVTR ($15.19), HALO ($110.76), GRFS ($7.88)
GGB (Gerdau S.A.): Leads 5 peers: TX ($57.98), CMC ($68.75), CLF ($12.28), EXP ($193.58), NEU ($900.15)
Recent Headlines
ALNY (Alnylam Pharmaceuticals, Inc.)
- Alnylam to Webcast Presentations at Upcoming September Investor Conferences
ALV (Autoliv, Inc.)
- Alvopetro reports August sales volumes, provides operational update
ATR (AptarGroup, Inc.)
- CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
BLTE (Belite Bio, Inc)
- Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
- Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (10 signals) suggests sector-specific rotation. 3 signals showing insider selling warrant caution.
Trading tips for this strategy:
- Entry timing: Enter on pullback after crossover or at crossover close price
- Position sizing: Start with 2-3% of portfolio per signal (swing trade size)
- Stop loss: Below recent swing low for buys, above recent swing high for sells
- Take profit: 5-10% target for swings, or trail stop at EMA10
- Time stop: Exit if crossover reverses within 1-2 weeks (failed signal)
Risk warning: EMA crossovers generate more signals but higher whipsaw risk in ranging markets. Use with trend filter (price vs SMA200)
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.